Publications by authors named "Jonathan Cebon"

Claim this Profile
E
Effects of CVA21, an Oncolytic Virus, in Combination with Pembrolizumab on Immunogenicity and the Tumor Microenvironment in Advanced NSCLC: A Phase I/II Trial.
Adithya Balasubramanian, Claire Marceaux, Sehrish Kanwal, Ilariya Tarasova, Daniel Batey, Jonathan Cebon

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab and Ipilimumab in Advanced Mismatch Repair-Deficient/Microsatellite Instability-High Noncolorectal Cancers: A Nonrandomized Clinical Trial.
Matteo S Carlino, Bo Gao, Michael Michael, Henry Marshall, Ashray Gunjur, Jonathan Cebon

JAMA Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers: A Nonrandomized Clinical Trial.
Bo Gao, Matteo S Carlino, Michael Michael, Craig Underhill, Henry Marshall, Jonathan Cebon

JAMA Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Common inherited loss-of-function mutations in the innate sensor NOD2 contribute to exceptional immune response to cancer immunotherapy.
Megan B Barnet, Katherine J L Jackson, Etienne Masle-Farquhar, Amanda Russell, Deborah L Burnett, Jonathan Cebon

Proc Natl Acad Sci U S A· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A gut microbial signature for combination immune checkpoint blockade across cancer types.
Ashray Gunjur, Yan Shao, Timothy Rozday, Oliver Klein, Andre Mu, Jonathan Cebon

Nat Med· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable response to combination immunotherapy using nivolumab and ipilimumab in metastatic succinate dehydrogenase (SDH)-deficient gastrointestinal stroma tumour.
Oliver Klein, Jodie Palmer, Andreas Behren, Jonathan Cebon, Damien Kee

Eur J Cancer· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is there a role for combined anti-PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers?
Oliver Klein, Damien Kee, Adnan Nagrial, Ben Markman, Craig Underhill, Jonathan Cebon

Cancer· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.
Simone M Goldinger, Kristina Buder-Bakhaya, Serigne N Lo, Andrea Forschner, Meredith McKean, Jonathan Cebon

Eur J Cancer· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial.
Oliver Klein, Damien Kee, Bo Gao, Ben Markman, Jessica da Gama Duarte, Jonathan Cebon

J Immunother Cancer· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma.
Sagun Parakh, Ashan Musafer, Sabrina Paessler, Tom Witkowski, Connie S N Li Wai Suen, Jonathan Cebon

Front Immunol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules.
Georgina V Long, Caroline Robert, Marcus O Butler, Felix Couture, Matteo S Carlino, Jonathan S Cebon

Clin Cancer Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma.
Nicolas Jacquelot, Cyril Seillet, Minyu Wang, Angela Pizzolla, Yang Liao, Jonathan Cebon

Nat Immunol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma.
Surein Arulananda, Megan O'Brien, Marco Evangelista, Tiffany J Harris, Nikita S Steinohrt, Jonathan Cebon

Cell Death Discov· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy.
Oliver Klein, Damien Kee, Ben Markman, Matteo S Carlino, Craig Underhill, Jonathan Cebon

Cancer Cell· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma.
Surein Arulananda, Megan O'Brien, Marco Evangelista, Laura J Jenkins, Ashleigh R Poh, Jonathan Cebon

Cell Death Discov· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538.
Oliver Klein, Clare Senko, Matteo S Carlino, Ben Markman, Louise Jackett, Jonathan Cebon

Oncoimmunology· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ropporin-1 and 1B Are Widely Expressed in Human Melanoma and Evoke Strong Humoral Immune Responses.
Jessica Da Gama Duarte, Katherine Woods, Luke T Quigley, Cyril Deceneux, Candani Tutuka, Jonathan Cebon

Cancers (Basel)· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Migratory cues controlling B-lymphocyte trafficking in human lymph nodes.
Saem Mul Park, Anna Es Brooks, Chun-Jen J Chen, Hilary M Sheppard, Evert Jan Loef, Jonathan Cebon

Immunol Cell Biol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B.
Matteo S Carlino, Alexander M Menzies, Victoria Atkinson, Jonathan S Cebon, Michael B Jameson

Clin Cancer Res· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma.
Pouya Faridi, Katherine Woods, Simone Ostrouska, Cyril Deceneux, Ritchlynn Aranha, Jonathan S Cebon

Cancer Immunol Res· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BCL-XL is an actionable target for treatment of malignant pleural mesothelioma.
Surein Arulananda, Megan O'Brien, Marco Evangelista, Tiffany J Harris, Nikita S Steinohrt, Jonathan Cebon

Cell Death Discov· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial.
Oliver Klein, Damien Kee, Adnan Nagrial, Ben Markman, Craig Underhill, Jonathan Cebon

JAMA Oncol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.
Sebastian Hultin, Kazi Nahar, Alexander M Menzies, Georgina V Long, Suran L Fernando, Jonathan Cebon

BMC Nephrol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinctive Subpopulations of Stromal Cells Are Present in Human Lymph Nodes Infiltrated with Melanoma.
Jennifer Eom, Saem Mul Park, Vaughan Feisst, Chun-Jen J Chen, Joanna E Mathy, Jonathan S Cebon

Cancer Immunol Res· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pilot study of intrahepatic yttrium-90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver-only metastases.
Surein Arulananda, Sagun Parakh, Jodie Palmer, Mark Goodwin, Miles C Andrews, Jonathan Cebon

Cancer Rep (Hoboken)· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis